Clinical trial NCT01016054: A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
Official title: A Phase 1b, Parallel Arm, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Two Different Chemotherapy Regimens in Women With Platinum Resistant or Platinum Sensitive Ovarian Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Carcinoma
Ovarian Cancer
Ovarian Diseases
Ovarian Neoplasms
Keywords: Clinical Trial, Phase1
Combination Drug Therapy
pharmacokinetics
safety
Ovarian
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
Collaborators: name: Agensys, Inc.
First posted: 2009-11-18
Enrollment: 4
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a parallel arm study to evaluate AGS-8M4 administered in combination with chemotherapy in subjects with ovarian cancer. AGS-8M4 will be administered as an IV infusion until disease worsens.

Detailed description: All Subjects will receive AGS-8M4 treatment. Subjects will be enrolled into 1 of 2 treatment arms according to their disease status. A disease assessment will be performed every 8 or 9 weeks (± 3 days) depending on the treatment arm assignment. The assessment will be based both on changes in clinical symptoms, and radiographic images. Subjects without evidence of disease progression may continue to receive treatment based on their original treatment assignment until disease progression or intolerability. A safety follow-up visit will occur 4 weeks after the last dose infusion of AGS-8M4.

Eligibility criteria: Inclusion Criteria:

* Subjects with recurrent disease Stage III/IV diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma
* Subjects with either platinum resistant or platinum sensitive ovarian cancer
* At least 14 days of previous cytotoxic chemotherapy and have recovered from all toxicities
* Left ventricular ejection fraction (LVEF) equal to or greater than the institutional lower limit of normal as measured by echocardiogram or MUGA (ONLY required for platinum resistant patients)

Exclusion Criteria:

* Active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) within 72 hours of screening
* Use of any investigational drug within 30 days prior to screening
* Prior monoclonal antibody therapy other than Avastin
* Avastin administration within 90 days of screening
* History of thromboembolic events and bleeding disorders ≤ 3 months (e.g.,DVT or PE)

Primary outcomes:
measure: Incidence of adverse events
timeFrame: Throughout the treatment
Secondary outcomes:
measure: Assessment of PK variables
timeFrame: Treatment Arm A: Weeks 1 and 3 of each cycle. Treatment Arm B: Week 1 of each cycle. In addition, samples will be drawn at the Safety F/U, 2 Month F/U and 3 Month F/U visits.
measure: Incidence of anti-AGS-8M4 antibody formation
timeFrame: Treatment Arm A: Day 1 of every other cycle and at Day 15 for the first cycle only. Treatment Arm B: Day 1 of every other cycle. In addition, samples will be drawn at the Safety F/U, 2 Month F/U and 3 Month F/U visits.
measure: Changes in tumor status per RECIST
timeFrame: Treatment Arm A: Every 8 weeks. Treatment Arm B: Every 9 weeks.
measure: Change in CA-125 levels
timeFrame: Treatment Arm A: Day 1 and Day 15 of each cycle. Treatment Arm B: Day 1 of each cycle. In addition, samples will be drawn at the Safety F/U.
Other outcomes:
Locations:
city: Duarte
country: United States
state: California
Study officials:
affiliation: Agensys, Inc.
name: Use Central Contact
role: STUDY_DIRECTOR
References: